{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:06:15Z","timestamp":1780934775752,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,2]],"date-time":"2027-04-02T00:00:00Z","timestamp":1806624000000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hpb.2025.12.021","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:10:04Z","timestamp":1765818604000},"page":"480-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy"],"prefix":"10.1016","volume":"28","author":[{"given":"Yusuke","family":"Kazami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikuni","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunaga","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naminatsu","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Kiritani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5976-6041","authenticated-orcid":false,"given":"Yuichiro","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ichida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0455-6412","authenticated-orcid":false,"given":"Takeshi","family":"Takamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4074-1140","authenticated-orcid":false,"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-740X","authenticated-orcid":false,"given":"Kiyoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2025.12.021_bib1","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","article-title":"Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors","volume":"18","author":"Klein","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2025.12.021_bib2","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","article-title":"Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention","volume":"164","author":"Stoffel","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.hpb.2025.12.021_bib3","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1245\/s10434-009-0413-9","article-title":"Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement","volume":"16","author":"Abrams","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.021_bib4","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.021_bib5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","article-title":"Borderline resectable pancreatic cancer: a consensus statement by the international study group of pancreatic surgery (ISGPS)","volume":"155","author":"Bockhorn","year":"2014","journal-title":"Surgery"},{"key":"10.1016\/j.hpb.2025.12.021_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jamcollsurg.2007.12.020","article-title":"Borderline resectable pancreatic cancer: the importance of this emerging stage of disease","volume":"206","author":"Katz","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.hpb.2025.12.021_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.hpb.2025.12.021_bib8","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pan.2020.11.026","article-title":"High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment","volume":"21","author":"Ushida","year":"2021","journal-title":"Pancreatology"},{"key":"10.1016\/j.hpb.2025.12.021_bib9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hpb.2025.12.021_bib10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hpb.2025.12.021_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/JS9.0000000000000792","article-title":"Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis","volume":"110","author":"Leonhardt","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.hpb.2025.12.021_bib12","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2025.12.021_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41575-023-00856-2","article-title":"Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer","volume":"21","author":"Stoop","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2025.12.021_bib14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jhbp.844","article-title":"Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: intention-to-treat analysis compared with upfront surgery","volume":"28","author":"Inoue","year":"2021","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.hpb.2025.12.021_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.021_bib16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.hpb.2025.12.021_bib17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.pan.2023.10.014","article-title":"Combination of carbohydrate antigen 19-9 level and tumor size after neoadjuvant chemoradiation therapy may predict early recurrence of resectable pancreatic ductal adenocarcinoma","volume":"23","author":"Terai","year":"2023","journal-title":"Pancreatology"},{"key":"10.1016\/j.hpb.2025.12.021_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102285","article-title":"Perioperative predictors of early recurrence for resectable and borderline-resectable pancreatic cancer","volume":"13","author":"Imamura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.hpb.2025.12.021_bib19","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.ejso.2019.04.007","article-title":"Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer","volume":"45","author":"Groot","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.021_bib20","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.hpb.2025.12.021_bib21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hpb.2025.12.021_bib22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s00535-023-01988-7","article-title":"Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan Pancreas Society","volume":"58","author":"Tomimaru","year":"2023","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.hpb.2025.12.021_bib23","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.surg.2020.02.013","article-title":"A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma","volume":"168","author":"Guo","year":"2020","journal-title":"Surgery"},{"key":"10.1016\/j.hpb.2025.12.021_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/JS9.0000000000000296","article-title":"Early and late recurrence patterns of pancreatic ductal adenocarcinoma after pancreaticoduodenectomy: a multicenter study","volume":"109","author":"Zhang","year":"2023","journal-title":"Int J Surg"},{"key":"10.1016\/j.hpb.2025.12.021_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hpb.2025.12.021_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s10637-018-0691-9","article-title":"A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer","volume":"37","author":"Saito","year":"2019","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.hpb.2025.12.021_bib27","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10637-020-01022-0","article-title":"A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel","volume":"39","author":"Saito","year":"2021","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.hpb.2025.12.021_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.021_bib29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","article-title":"Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"127","author":"Evans","year":"1992","journal-title":"Arch Surg"},{"key":"10.1016\/j.hpb.2025.12.021_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.hpb.2025.12.021_bib31","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1245\/s10434-022-11579-0","article-title":"Recurrence after resection of pancreatic cancer: can radiomics predict patients at greatest risk of liver metastasis?","volume":"29","author":"Zambirinis","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.021_bib32","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1245\/s10434-012-2809-1","article-title":"CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy","volume":"20","author":"Hartwig","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.021_bib33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.hpb.2022.09.012","article-title":"Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels","volume":"25","author":"Ono","year":"2023","journal-title":"HPB"},{"key":"10.1016\/j.hpb.2025.12.021_bib34","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.hpb.2024.01.017","article-title":"Can preoperative Carbohydrate Antigen 19-9 predict metastatic pancreatic cancer? Results of a systematic review and meta-analysis","volume":"26","author":"Raza","year":"2024","journal-title":"HPB"},{"key":"10.1016\/j.hpb.2025.12.021_bib35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1634\/theoncologist.2019-0878","article-title":"Sustained carbohydrate antigen 19-9 response to neoadjuvant chemotherapy in borderline resectable pancreatic cancer predicts progression and survival","volume":"25","author":"Rose","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.hpb.2025.12.021_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.021_bib37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/SLA.0000000000003049","article-title":"Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer","volume":"271","author":"Tsai","year":"2020","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.021_bib38","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1245\/s10434-021-10991-2","article-title":"Neoadjuvant chemotherapy switch in borderline resectable\/locally advanced pancreatic cancer","volume":"29","author":"Alva-Ruiz","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.021_bib39","doi-asserted-by":"crossref","first-page":"e1278","DOI":"10.1097\/SLA.0000000000005395","article-title":"Serum DUPAN-2 could be an alternative biological marker for CA19-9 nonsecretors with pancreatic cancer","volume":"277","author":"Omiya","year":"2023","journal-title":"Ann Surg"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25017538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25017538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:24:11Z","timestamp":1775121851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X25017538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1365182X25017538"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2025.12.021","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing surgical indication in patients with borderline resectable pancreatic ductal adenocarcinoma to prevent futile pancreatectomy","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2025.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}